Filing summary
Issuer and period: The supplied metadata identifies Tuhura Biosciences, Inc., but the filing itself is for Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.; Nasdaq: KTRA). It is a Form 10-Q for the quarter and six months ended December 31, 2020—Kintara’s fiscal second quarter. The filing text does not establish that it belongs to Tuhura.
Business context and operating update
Kintara is a clinical-stage cancer drug developer with no revenue to date. Its lead programs are VAL-083 for glioblastoma (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC). In August 2020, it completed its merger with Adgero, acquired the REM-001 assets, changed its name, and raised capital through a Series C preferred-stock placement.
Patient recruitment for VAL-083’s GBM AGILE registration study began in January 2021. Management also reported planned milestones including VAL-083 Phase 2 data updates and initial REM-001 study enrollment and results; these are plans, not reported outcomes.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in thousands except per-share data.
| Metric | Three months ended Dec. 31, 2020 | Six months ended Dec. 31, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $2,584 | $3,941 | $712 and $1,434 |
| General and administrative expense | $2,794 | $4,329 | $1,054 and $1,967 |
| Net loss | $5,413 | $24,931 | $1,740 and $3,346 |
| Basic and diluted loss per share | $0.22 | $1.34 | $0.15 and $0.35 |
| Net cash used in operations | Not clearly stated for the quarter | $9,541 | $3,977 used |
The six-month loss included a $16.1 million noncash charge for acquired in-process research and development and $0.5 million of merger costs. The quarter’s operating expenses rose year over year, reflecting clinical-program activity, personnel costs, and share-based compensation. As a clinical-stage company without revenue, conventional profit margins are not meaningful.
At December 31, 2020, cash and cash equivalents were $17.2 million, working capital was $15.0 million, total assets were $20.5 million, total liabilities were $2.9 million, and stockholders’ equity was $17.6 million. Cash increased from $2.4 million at June 30, 2020. Six-month financing cash flow was $23.3 million, mainly from approximately $21.6 million net Series C proceeds, warrant exercises, and a $0.5 million loan; investing cash flow included $0.97 million acquired in the merger.
The $0.5 million National Brain Tumor Society/National Foundation for Cancer Research loan bears 6% interest and matures June 19, 2021. The balance-sheet carrying amount was $0.473 million net of deferred loan costs.
Material changes, outlook, and risks
- The Adgero merger expanded the pipeline to include REM-001 and led to a $16.1 million acquired IPR&D expense. Kintara raised approximately $25 million gross, or $21.6 million net, in Series C financing.
- Management stated cash was expected to fund planned operations into the fourth quarter of calendar 2021, but also said additional funding would be needed. The financial statements disclose substantial doubt about the company’s ability to continue as a going concern within one year of filing. Management was pursuing equity financing and/or strategic partnerships; success was not assured.
- Further equity financing could dilute shareholders. Series C preferred stock was convertible into substantial common shares and carries share dividends; outstanding options and warrants add potential dilution. Subsequent to quarter-end, the company reported additional warrant exercises and Series C conversions.
- Management expected fiscal 2021 R&D costs to exceed fiscal 2020 as GBM AGILE and REM-001 work progressed. Clinical, regulatory, manufacturing, financing, and trial-enrollment outcomes remain uncertain. COVID-19 had not significantly disrupted studies to date, though clinical monitor access had been limited and capital-market effects remained uncertain.
- VAL-083’s reported Phase 2 results were company-reported and compared with historical controls, not head-to-head trials. Myelosuppression, including thrombocytopenia, was identified as a key safety concern. REM-001’s supporting CMBC data came from historical studies conducted by Miravant; Kintara planned a new pivotal study.
- Disclosure controls and procedures were reported as ineffective due to a material weakness previously described in the 2020 Form 10-K. The company reported no legal proceedings and no off-balance-sheet arrangements; it listed no new risk factors in this 10-Q.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for Kintara Therapeutics, Inc., not Tuhura Biosciences, Inc.
- Review the going-concern disclosure against cash use, stated runway, and the timing and availability of new financing.
- Assess fully diluted share exposure from Series C conversion rights and dividends, warrants, options, and post-quarter exercises and conversions.
- Verify clinical-trial progress, enrollment, timelines, regulatory requirements, and the evidentiary basis for management’s efficacy statements.
- Review the prior Form 10-K discussion of the material weakness and any remediation progress.